24/7 Market News Snapshot 15 July, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)
DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (NASDAQ:SXTP) are discussed in this article.
60 Degrees Pharmaceuticals, Inc. (SXTP), a leader in developing solutions for infectious diseases, is currently facing a bearish trend, as evidenced by its pre-market trading at $2.033, down 6.1% from the previous close of $2.165. This decline coincides with a significant trading volume of 19.27 million shares, indicative of increased market activity typically seen during corrective phases. Technical analysis highlights a resistance point at the prior support level of $2.00; if the stock maintains levels below this, there may be increased downside risk. Conversely, a recovery above $2.10 could foster renewed bullish sentiment among investors. Stakeholders are advised to closely scrutinize trading volumes and trend patterns to assess the stock’s forthcoming trajectory amidst prevailing bearish pressures.
In a positive development for the Company, 60 Degrees Pharmaceuticals has successfully completed the pricing of a public offering, consisting of 2,631,578 shares of common stock and associated warrants priced at $1.90 per share. The Series A-1 warrants will be immediately exercisable for five years, with the Series A-2 warrants available for 18 months, both at the same exercise price. The offering aims to raise approximately $5 million in gross proceeds, with a potential additional $5 million if the Series A-2 warrants are fully exercised. Proceeds from this offering are earmarked for operational support and general corporate purposes, bolstering the Company’s commitment to research and development.
As the Company continues its mission to deliver innovative therapies, including the FDA-approved ARAKODA® for malaria prevention, 60 Degrees Pharmaceuticals remains focused on advancing public health through strategic investments in new medicinal solutions. The offering is underpinned by a registration statement effective since July 15, 2025, with detailed information available on the SEC’s website, ensuring transparency for potential investors.
Related news for (SXTP)
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 60 Degrees Pharmaceuticals Targets Human and Canine Babesiosis Markets With Tafenoquine
- Today’s Top Performers: MoBot’s Market Review 07/15/25 07:00 AM
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion